rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jonathan Anderman

General Counsel

Company insider

Files Form 4 as: General Counsel, Compass Therapeutics.

In numbers

Trades disclosed
11
Buys
2
Sells
0
Bought
$125K
Sold
$0
Companies
1
Companies where not an officer
0
First trade
13 Aug 2024
Last trade
29 Apr 2026
Last filed
30 Apr 2026

Companies traded

Where they are an officer
CMPX Compass TherapeuticsOfficer · Biotechnology · last 29 Apr 20262 buys · 0 sells

Activity over time

1 Apr 2025 – 1 Oct 2026
01Apr 25Sep 25Jan 26Jun 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
29 Apr 2026filed 30 Apr 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Bought$47K25,000 at $1.89filing
29 Apr 2026filed 30 Apr 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Bought$47K25,000 at $1.89filing
29 Apr 2026filed 29 Apr 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Code A$47K25,000 at $1.89filing
29 Apr 2026filed 29 Apr 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Code A$47K25,000 at $1.89filing
2 Jan 2026filed 5 Jan 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Code A$776K150,000 at $5.17filing
2 Jan 2026filed 5 Jan 2026CMPX Compass Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—720,000 at $0.00filing
2 Jan 2026filed 5 Jan 2026CMPX Compass Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—720,000 at $0.00filing
2 Jan 2026filed 5 Jan 2026CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Code A$776K150,000 at $5.17filing
7 Apr 2025filed 8 Apr 2025CMPX Compass TherapeuticsBiotechnologySEC FORM 4 Bought$31K20,000 at $1.54filing
11 Feb 2025filed 13 Feb 2025CMPX Compass Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—280,000 at $0.00filing
13 Aug 2024filed 14 Aug 2024CMPX Compass Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—300,000 at $0.00filing

News

Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21CMPX · dailypolitical.com · 11 Oct 2026

0 headlines in the last 90 days name Jonathan Anderman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Neil LernerChief Accounting Officer · Chief Accounting Officer at Compass Therapeutics, filing Form 4 there in the last year
Thomas J. SchuetzChief Executive Officer · Chief Executive Officer at Compass Therapeutics, filing Form 4 there in the last year
Carl L. GordonDirector and 10% owner · Director at Compass Therapeutics, filing Form 4 there in the last year
Ellen ChiniaraDirector · Director at Compass Therapeutics, filing Form 4 there in the last year
Barry ShinCFO · CFO at Compass Therapeutics, filing Form 4 there in the last year